JP2011503202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503202A5 JP2011503202A5 JP2010534206A JP2010534206A JP2011503202A5 JP 2011503202 A5 JP2011503202 A5 JP 2011503202A5 JP 2010534206 A JP2010534206 A JP 2010534206A JP 2010534206 A JP2010534206 A JP 2010534206A JP 2011503202 A5 JP2011503202 A5 JP 2011503202A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- peptide substrate
- protease
- item
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 35
- 108091005771 Peptidases Proteins 0.000 claims description 32
- 239000004365 Protease Substances 0.000 claims description 32
- 230000002401 inhibitory effect Effects 0.000 claims description 32
- 239000000758 substrate Substances 0.000 claims description 31
- 102000033147 ERVK-25 Human genes 0.000 claims description 29
- 206010013774 Dry eye Diseases 0.000 claims description 18
- 101700067851 MMP9 Proteins 0.000 claims description 13
- 102100006844 MMP9 Human genes 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 10
- OMDQUFIYNPYJFM-XKDAHURESA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[[(2R,3S,4R,5S,6R)-4,5,6-trihydroxy-3-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims description 7
- 101700064369 A2M Proteins 0.000 claims description 7
- 102100000684 A2M Human genes 0.000 claims description 7
- 229920000926 Galactomannan Polymers 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 101700002274 PZP Proteins 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- 108010035532 Collagen Proteins 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 229960005188 collagen Drugs 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 108010076119 Caseins Proteins 0.000 claims description 4
- 239000005018 casein Substances 0.000 claims description 4
- 235000021240 caseins Nutrition 0.000 claims description 4
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 108010000416 ovomacroglobulin Proteins 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 claims description 2
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims description 2
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims description 2
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims description 2
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims description 2
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims description 2
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 claims description 2
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000003115 biocidal Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 229940079866 intestinal antibiotics Drugs 0.000 claims description 2
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims description 2
- 230000000699 topical Effects 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 2
- 210000001138 Tears Anatomy 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000001519 tissues Anatomy 0.000 description 4
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 3
- 229940012356 Eye Drops Drugs 0.000 description 3
- 102000035443 Peptidases Human genes 0.000 description 3
- 230000004397 blinking Effects 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 210000002919 epithelial cells Anatomy 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000002335 preservative Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010040767 Sjogren's syndrome Diseases 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- DPFYBZWSVVKNPZ-AQWIXGDGSA-N (3S,4S,6R)-2-[[(2R,4R,5R)-3,5-dihydroxy-4-methoxy-6-(methoxymethyl)oxan-2-yl]methoxymethyl]-6-ethyloxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)C(O)[C@@H](CC)OC1COC[C@@H]1C(O)[C@H](OC)[C@H](O)C(COC)O1 DPFYBZWSVVKNPZ-AQWIXGDGSA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (Z,12R)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- 229920001429 Chelating resin Polymers 0.000 description 1
- 210000000795 Conjunctiva Anatomy 0.000 description 1
- 210000004087 Cornea Anatomy 0.000 description 1
- 229940119743 Dextran 70 Drugs 0.000 description 1
- 206010013781 Dry mouth Diseases 0.000 description 1
- 210000003499 Exocrine Glands Anatomy 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 210000004907 Glands Anatomy 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 101700060512 MMP2 Proteins 0.000 description 1
- 102100014894 MMP2 Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 229940051875 Mucins Drugs 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 210000000440 Neutrophils Anatomy 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 210000002826 Placenta Anatomy 0.000 description 1
- 229940068918 Polyethylene Glycol 400 Drugs 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 210000003296 Saliva Anatomy 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 208000005494 Xerophthalmia Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000003281 allosteric Effects 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- 229940058933 biguanide antimalarials Drugs 0.000 description 1
- 229940090145 biguanide blood glucose lower drugs Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 230000000254 damaging Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 230000001502 supplementation Effects 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98862307P | 2007-11-16 | 2007-11-16 | |
| PCT/US2008/083551 WO2009064983A1 (en) | 2007-11-16 | 2008-11-14 | Methods and compositions for treating dry eye |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011503202A JP2011503202A (ja) | 2011-01-27 |
| JP2011503202A5 true JP2011503202A5 (xx) | 2012-12-06 |
Family
ID=40347942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010534206A Pending JP2011503202A (ja) | 2007-11-16 | 2008-11-14 | ドライアイを処置するための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090131303A1 (xx) |
| EP (1) | EP2207598A1 (xx) |
| JP (1) | JP2011503202A (xx) |
| KR (1) | KR20100087188A (xx) |
| CN (1) | CN101861187A (xx) |
| AU (1) | AU2008322545A1 (xx) |
| BR (1) | BRPI0819331A2 (xx) |
| CA (1) | CA2703814A1 (xx) |
| RU (1) | RU2470662C2 (xx) |
| TW (1) | TW200930383A (xx) |
| WO (1) | WO2009064983A1 (xx) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1400996B1 (it) * | 2010-06-14 | 2013-07-05 | Silvestrini | Metodo per il trattamento dell'occhio secco con gelatina somministrata per via orale |
| US9453833B2 (en) | 2011-01-07 | 2016-09-27 | Digital Diagnostics Pty. Ltd. | System and method for detecting and monitoring proteolysis of protein matrices |
| RU2013136826A (ru) * | 2011-01-07 | 2015-02-20 | Те Юниверсити Оф Квинсленд | Детекция протеолиза |
| KR20140016275A (ko) * | 2011-01-24 | 2014-02-07 | 안테리오스, 인코퍼레이티드 | 비어있는 나노입자의 조성물 및 피부 질환을 치료하기 위한 그의 용도 |
| US9138481B2 (en) * | 2011-12-06 | 2015-09-22 | Alcon Research, Ltd. | Cellulosic gel composition with improved viscosity stability |
| EP2950800B1 (en) | 2013-02-01 | 2020-09-09 | Ocuphire Pharma, Inc. | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance |
| DK2950648T3 (da) | 2013-02-01 | 2019-12-02 | Ocuphire Pharma Inc | Vandige oftalmiske opløsninger af phentolamin og medicinske anvendelser deraf |
| KR101692578B1 (ko) * | 2013-04-18 | 2017-01-03 | 삼진제약주식회사 | 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물 |
| KR101721059B1 (ko) * | 2014-12-26 | 2017-03-30 | 주식회사 아이바이오코리아 | 안구 표면 질환 예방 또는 치료용 약학조성물 |
| US10071181B1 (en) * | 2015-04-17 | 2018-09-11 | Teleflex Innovations S.À.R.L. | Resorbable embolization spheres |
| KR101690539B1 (ko) | 2015-07-30 | 2016-12-29 | 주식회사 아이바이오코리아 | 건성안 예방 또는 치료용 약학조성물 |
| US10632202B2 (en) | 2016-03-04 | 2020-04-28 | Johnson & Johnson Consumer Inc. | Preservative containing compositions |
| KR101798183B1 (ko) | 2016-04-08 | 2017-11-15 | 주식회사 아이바이오코리아 | 건성안 예방 또는 치료용 약학조성물 |
| ES2819030T3 (es) | 2016-04-08 | 2021-04-14 | Eyebio Korea | Péptido basado en colágeno tipo II alfa-1 útil para el tratamiento de una enfermedad de la superficie ocular |
| RU2620568C1 (ru) * | 2016-04-12 | 2017-05-26 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПбГПМУ Минздрава России) | Препарат для лечения синдрома "сухого глаза" |
| RU2646804C1 (ru) * | 2016-12-28 | 2018-03-07 | федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) | Офтальмологическое средство для регенерации роговицы глаза |
| JP2020520372A (ja) * | 2017-05-17 | 2020-07-09 | ユーユー ファーマ，インコーポレーテッド | 新規ペプチド及びその新規ペプチドを活性成分として含む眼疾患の治療のための医薬組成物 |
| RU2677190C1 (ru) * | 2017-11-28 | 2019-01-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) | Способ лечения патологии суммарной слезопродукции у пациентов с ревматоидным артритом |
| EP3870170A4 (en) | 2018-10-26 | 2022-07-20 | Ocuphire Pharma, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES |
| US11613558B2 (en) | 2018-11-14 | 2023-03-28 | Yuyu Pharma, Inc. | Peptides and pharmaceutical compositions for treating eye diseases |
| TWI757773B (zh) | 2019-06-28 | 2022-03-11 | 瑞士商愛爾康公司 | 眼用組成物 |
| JP7419499B2 (ja) | 2019-09-18 | 2024-01-22 | アルコン インク． | 湿式充填のソフトヒドロゲル眼用インサート |
| US20210196652A1 (en) * | 2019-12-27 | 2021-07-01 | Meshaberase, LLC | Use of cysteamine and derivatives thereof to treat dysfunctional tear syndrome (dts) |
| CN115368310A (zh) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
| CN113713086A (zh) * | 2021-08-20 | 2021-11-30 | 山西锦波生物医药股份有限公司 | 一种含有重组iii型人源化胶原蛋白的组合物及其制备方法和用途 |
| US20230310615A1 (en) * | 2022-03-31 | 2023-10-05 | Alcon Inc. | Ophthalmic compositions |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4039662A (en) * | 1975-12-04 | 1977-08-02 | Alcon Laboratories, Inc. | Ophthalmic solution |
| US4365050A (en) * | 1981-07-15 | 1982-12-21 | Ivani Edward J | Amino-polysaccharides and copolymers thereof for contact lenses and ophthalmic compositions |
| US4447562A (en) * | 1981-07-15 | 1984-05-08 | Ivani Edward J | Amino-polysaccharides and copolymers thereof for contact lenses and ophthalmic compositions |
| US5112805A (en) * | 1985-11-22 | 1992-05-12 | Labsystems, Oy | Pharmaceutical preparation for promoting epithelial healing and prevention of epithelial destruction |
| FI854634A0 (fi) * | 1985-11-22 | 1985-11-22 | Labsystems Oy | Foerfarande foer bestaemning av proteolytisk aktivitet. |
| US5188826A (en) * | 1988-02-08 | 1993-02-23 | Insite Vision Incorporated | Topical ophthalmic suspensions |
| US4923700A (en) * | 1988-06-03 | 1990-05-08 | Kaufman Herbert E | Artificial tear suspension |
| DE3827561C1 (xx) * | 1988-08-13 | 1989-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
| RU2094031C1 (ru) * | 1992-04-09 | 1997-10-27 | Малое государственное предприятие "Научно-экспериментальное производство" | Способ профилактики новообразованных сосудов роговицы после сквозной и послойной кератопластики |
| JPH06256209A (ja) * | 1993-03-03 | 1994-09-13 | Fuji Yakuhin Kogyo Kk | 眼球及びその周辺部組織の潰瘍に対する予防・治療剤 |
| US5652209A (en) * | 1994-04-29 | 1997-07-29 | University Of Miami | Use of secretory products of human lacrimal gland acinar epithelia for tear replacement therapy |
| US5698533A (en) * | 1994-07-26 | 1997-12-16 | Kang; Meng-Che | Ophthalmic pharmaceutical composition |
| US5518732A (en) * | 1995-02-14 | 1996-05-21 | Chiron Vision, Inc. | Bio-erodible ophthalmic shield |
| US5888493A (en) * | 1996-12-05 | 1999-03-30 | Sawaya; Assad S. | Ophthalmic aqueous gel formulation and related methods |
| GB2320431B (en) * | 1996-12-20 | 2000-08-30 | Johnson & Johnson Medical | Compositions for the treatment of chronic wounds |
| US5800807A (en) * | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| DE69818675T2 (de) * | 1997-07-29 | 2004-07-29 | Alcon Laboratories, Inc., Fort Worth | Galaktomannanpolymere und borat enthaltende augenarzneimittel |
| JP4860038B2 (ja) * | 1998-05-08 | 2012-01-25 | ユニバーシティ オブ マイアミ | マイボーム腺疾病の処置におけるテトラサイクリン類の使用 |
| US6217896B1 (en) * | 1999-04-01 | 2001-04-17 | Uab Research Foundation | Conjunctival inserts for topical delivery of medication or lubrication |
| ATE435031T1 (de) * | 1999-07-13 | 2009-07-15 | Univ Southern California | Methode und zusammensetzung zur angiogenese- inhibierung mit antagonisten gegen mmp-9 und beta1-integrine |
| AU1101501A (en) * | 1999-10-27 | 2001-05-08 | K-Quay Enterprises, Llc | Methods and compositions for treatment of keratoconus using protease inhibitors |
| AU2002232437A1 (en) * | 2000-12-20 | 2002-07-01 | Alcon Universal Ltd. | Ophthalmic lubricating solution adapted for use in lasik surgery |
| US20030215471A1 (en) * | 2001-01-31 | 2003-11-20 | Wilmott James M. | Surfactant free topical compositions and method for rapid preparation thereof |
| US20030223957A1 (en) * | 2002-04-10 | 2003-12-04 | Schwartz Daniel M. | Biodegradable PEG based polymer formulations in ocular applications |
| EP1720555A1 (en) * | 2004-02-26 | 2006-11-15 | Advanced Ocular Systems Limited | Tetracycline derivatives for the treatment of ocular pathologies |
| US20060074108A1 (en) * | 2004-10-04 | 2006-04-06 | Bioderm Research | Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition |
| AU2006270041B2 (en) * | 2005-07-18 | 2011-08-18 | Minu, Llc | Enhanced ocular neuroprotection/neurostimulation |
| CN100381169C (zh) * | 2005-09-08 | 2008-04-16 | 佟刚 | 复合胶原蛋白滴眼液 |
| BRPI0714587A2 (pt) * | 2006-07-25 | 2013-05-07 | Osmotica Corp | suluÇço oftÁlmica aquosa e uso da nesna |
-
2008
- 2008-11-13 US US12/270,406 patent/US20090131303A1/en not_active Abandoned
- 2008-11-14 EP EP08849518A patent/EP2207598A1/en not_active Withdrawn
- 2008-11-14 CN CN200880116145A patent/CN101861187A/zh active Pending
- 2008-11-14 TW TW097144131A patent/TW200930383A/zh unknown
- 2008-11-14 CA CA2703814A patent/CA2703814A1/en not_active Abandoned
- 2008-11-14 RU RU2010123929/15A patent/RU2470662C2/ru not_active IP Right Cessation
- 2008-11-14 JP JP2010534206A patent/JP2011503202A/ja active Pending
- 2008-11-14 WO PCT/US2008/083551 patent/WO2009064983A1/en active Application Filing
- 2008-11-14 BR BRPI0819331 patent/BRPI0819331A2/pt not_active IP Right Cessation
- 2008-11-14 KR KR1020107011654A patent/KR20100087188A/ko not_active Application Discontinuation
- 2008-11-14 AU AU2008322545A patent/AU2008322545A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503202A5 (xx) | ||
| RU2470662C2 (ru) | Способы и композиции для лечения сухости глаз | |
| JP5616620B2 (ja) | 非イオン性シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| EP1156809A1 (en) | Mucin containing ophthalmic preparations | |
| US20090238810A1 (en) | Ophthalmic composition | |
| WO2000037080A1 (en) | Ophthalmic compositions comprising pheniramine and povidone | |
| JP3455852B2 (ja) | 洗眼液組成物 | |
| JP5688954B2 (ja) | シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| WO2008109397A2 (en) | Novel ophthalmic compositions containing human recombinant lysozyme and use thereof for treating eye conditions and as contact lens solutions | |
| CN108697635B (zh) | 用于治疗与角膜-结膜表面改变有关的眼病的眼科组合物 | |
| Donshik et al. | Giant papillary conjunctivitis in frequent-replacement contact lens wearers: a retrospective study. | |
| JP5700479B2 (ja) | シリコーンハイドロゲルコンタクトレンズ用点眼剤 | |
| Balaram et al. | Phacoemulsification in patients after allogeneic bone marrow transplantation | |
| Notivol et al. | Treatment of chronic nonbacterial conjunctivitis with a cyclo-oxygenase inhibitor or a corticosteroid | |
| Schrage et al. | Relationship of eye burns with calcifications of the cornea? | |
| JP2002193815A (ja) | 眼手術用角膜乾燥防止点眼剤 | |
| RU2679319C1 (ru) | Гелеобразная искусственная слеза с антисептическим и репаративным действием | |
| JP4778262B2 (ja) | 角膜疾患治療剤 | |
| JP4778515B2 (ja) | 角膜疾患治療剤 | |
| SENDELE | Chemical hypersensitivity reactions | |
| JP2020090552A (ja) | シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| TR2021015778A2 (tr) | Multi̇fonksi̇yonlu ekonomi̇k kontakt lens temi̇zleme solüsyonu ve üreti̇m yöntemi̇ | |
| JP5542511B2 (ja) | コンタクトレンズ用眼科組成物 | |
| JP2018197271A (ja) | シリコーンハイドロゲルコンタクトレンズ用眼科組成物 | |
| JP2022512788A (ja) | アプタミンｃを有効成分として含む点眼液組成物 |